Humacyte, Inc. (NASDAQ:HUMA) Director Brady W. Dougan Sells 427,459 Shares

Humacyte, Inc. (NASDAQ:HUMA) Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the transaction, the director now directly owns 1,992,253 shares in the company, valued at $8,646,378.02. This trade represents a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Humacyte Stock Down 0.2 %

Humacyte stock opened at $4.41 on Thursday. Humacyte, Inc. has a twelve month low of $2.43 and a twelve month high of $9.97. The firm has a 50 day moving average price of $5.36 and a 200-day moving average price of $6.18. The company has a market capitalization of $555.04 million, a P/E ratio of -3.29 and a beta of 1.47. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61.

Hedge Funds Weigh In On Humacyte

Several institutional investors have recently modified their holdings of HUMA. nVerses Capital LLC purchased a new position in Humacyte during the 2nd quarter valued at about $28,000. Concurrent Investment Advisors LLC purchased a new stake in shares of Humacyte during the 3rd quarter valued at about $75,000. Principal Financial Group Inc. bought a new position in shares of Humacyte during the 2nd quarter valued at $83,000. FORA Capital LLC purchased a new position in shares of Humacyte during the 3rd quarter worth $96,000. Finally, Profund Advisors LLC purchased a new stake in shares of Humacyte in the second quarter worth $97,000. 44.71% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

HUMA has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 target price on shares of Humacyte in a research note on Friday, September 20th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Humacyte in a report on Wednesday, November 13th. EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Benchmark reiterated a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a research report on Thursday, October 10th. Finally, Piper Sandler set a $6.00 price objective on Humacyte and gave the company a “neutral” rating in a report on Friday, October 18th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Humacyte presently has a consensus rating of “Buy” and an average price target of $11.00.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.